Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center

Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.

Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.

Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.

Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.

Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.

Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.

Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.

Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.

A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.

The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.

A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.